Eprosartan: A review of its use in the management of hypertension

Drugs

Volumn 60, Issue 1, 2000, Pages 177-201

  Plosker, G L ^a   Foster, R H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE;

CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HEADACHE; HUMAN; HYPERTENSION; PHARYNGITIS; RECEPTOR AFFINITY; REVIEW; RHINITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033884963     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00009     Document Type: Review

References (89)

1. Eprosartan
2. Renin-angiotensin system: Biochemistry and mechanisms of action
3. Angiotensin-converting enzyme inhibitors in hypertension: A dozen years of experience
4. Pharmacology of the angiotensin II receptor antagonist, eprosartan
5. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data
6. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
7. Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: Evidence that ACE inhibitors may inhibit a kininase other than ACE
8. Angiotensin II receptor subtypes in the kidney
9. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy
10. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors
11. Recent developments in angiotensin II receptor research
12. Practical considerations of the pharmacology of angiotensin receptor blockers
13. Angiotensin II receptor subtypes: Selective antagonists and functional correlates
14. Angiotensin II receptor antagonists
15. Angiotensin II receptors and angiotensin II receptor antagonists
16. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK and F 108566
17. Characterization of renal angiotensin II receptors using subtype selective antagonists
18. 3H]SK and F 108566 as a radioligand for angiotensin type-1 receptor
19. 1 receptor subtype
20. 1 receptor is a single copy gene: Characterization in a stable cell line
21. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes
22. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles
23. Effects of losartan and eprosartan on prejunctional angiotensin II receptors in the rabbit ear artery [abstract no. O.50]
24. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK and F 108566, in rats and dogs
25. Eprosartan improves ultrasound and MRI indices of cardiac function, prevents renal dysfunction and reduces mortality in severe hypertension [abstract no. P.25]
26. Eprosartan increases vascular distensibility in a rat model of severe hypertension [abstract no. P.26]
27. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
28. Potential impact of competitive vs. insurmountable angiotensin II receptor antagonism on renal function [abstract no. P.21]
29. Effect of captopril and the nonpeptide angiotensin II antagonists, SK and F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis
30. Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats
31. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men
32. Overview of the renal hemodynamic effects of eprosartan, a novel angiotensin II receptor antagonist [abstract no. P.29]
33. 1-receptor antagonist, in sodium-replete healthy men
34. The angiotensin II receptor antagonist SK and F 108566 does not increase uric acid (UA) excretion in healthy men [abstract no. 45P]
35. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension
36. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study
37. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
38. The renal profile of eprosartan
39. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: Absolute bioavailability and effect of food
40. A dose proportionality study of eprosartan in healthy male volunteers
41. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease
42. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
43. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan
44. Effect of age and gender on the pharmacokinetics of eprosartan
45. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations
46. The metabolic fate of eprosartan in healthy subjects
47. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies
48. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
49. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
50. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
51. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus
52. Eprosartan does not affect the pharmacodynamics of warfarin
53. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
54. British Hypertension Society guidelines for hypertension management 1999: Summary
55. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
56. Efficacy and safety of eprosartan in severe hypertension
57. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients
58. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension
59. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
60. Efficacy and safety of eprosartan in patients with essential hypertension: Results of an 8-week, double-blind, placebo-controlled, multicenter trial [abstract no. P31.075]
61. Once-daily effects of the angiotensin receptor blocker, eprosartan on 24-hour blood pressure in patients with systemic hypertension [abstract]
62. Assessment of the angiotensin II receptor antagonist eprosartan, by office and ambulatory BP monitoring [abstract no. C17]
63. Role of trough to peak efficacy in the evaluation of antihypertensive therapy
64. Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor-induced cough
65. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension
66. 1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension
67. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
68. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
69. Safety and tolerability of eprosartan
70. Safety of eprosartan in elderly patients with hypertension
71. Angiotensin converting enzyme inhibitors and cough
72. Angiotensin-converting enzyme inhibitors and cough: A prospective evaluation in hypertension and in congestive heart failure
73. Persistent drug cough with enalapril: Incidence depends on method used
74. Cough and ACE-inhibitors
75. Sixth report of the Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressure
76. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
77. The implications of noncompliance with antihypertensive medication
78. Hypertension
79. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
80. Comparative antihypertensive effects of angiotensin II receptor antagonists
81. Eprosartan
82. The diastolic blood pressure in systolic hypertension
83. Isolated systolic hypertension in the elderly: Lessons from clinical trials and future directions
84. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
85. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
86. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group
87. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
88. Hypertension in diabetes study IV. Therapeutic requirements to maintain tight blood pressure control